Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rich Pharmaceuticals Inc RCHA

Alternate Symbol(s):  RCHAE

"Rich Pharmaceuticals Inc is a United States based development stage biopharmaceutical company. It is focused on the development on RP-323 for the treatment of Hodgkin's lymphoma (HL), Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells in the patients depleted of these elements due to various conditions. RP-323 is a naturally occurring compound that has properties suited for the treatment of patients with HL, and AML. RP-323 has an ability to convert cancer cells to no


Showcase News Releases

Calibre Mining Corp
Calibre Mining Completes Acquisition of El Limon and La Libertad Gold Mines From B2Gold
Valens Groworks Corp
Valens Reports Record Revenue, Adjusted EBITDA and Profitability for the Third Quarter of Fiscal 2019
MGX Renewables Inc - Ordinary Shares
MGX Renewables Inc. Announces Commercialization Milestone Agreement

More Showcase News Releases »

×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.